Search

Search Constraints

You searched for: Author/Creator Cibula, David

Search Results

1. 2022-RA-1174-ESGO Role of adjuvant therapy in intermediate-risk cervical cancer patients – SCCAN study sub-analysis. (20th October 2022)

2. 2022-RA-1257-ESGO MILACC Study: Is the manipulation with LN containing undetected micrometastases the underlying cause of higher rate of local recurrences in the LACC trial?. (20th October 2022)

3. 2022-RA-1301-ESGO The impact of hospital surgical volume on survival in early-stage cervical cancer treated with radical hysterectomy: a sub-analysis of the SCCAN study. (20th October 2022)

4. 2022-RA-1392-ESGO Tisotumab vedotin combinations with pembrolizumab or carboplatin in patients with recurrent/metastatic cervical cancer: interim results of ENGOT Cx8/GOG-3024/innovaTV205. (20th October 2022)

5. 2022-RA-1548-ESGO Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: addition of a new cohort using first-line tisotumab vedotin + pembrolizumab + carboplatin ± bevacizumab in recurrent/metastatic cervical cancer. (20th October 2022)

7. 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician's choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). (20th October 2022)

8. 2022-RA-222-ESGO Quality of life after extended pelvic exenterations. (20th October 2022)

9. 2022-RA-426-ESGO Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical impact in patients with cervical cancer: subgroup analysis of the SCCAN project. (20th October 2022)

10. 2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer. (20th October 2022)